Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes.

Nonsense mutations create premature termination codons (PTCs), activating the nonsense-mediated mRNA decay (NMD) pathway to degrade most PTC-containing mRNAs. The undegraded mRNA is translated, but translation terminates at the PTC, leading to no production of the full-length protein. This work presents targeted PTC pseudouridylation, an approach for nonsense suppression in human cells. Specifically, an artificial box H/ACA guide RNA designed to target the mRNA PTC can suppress both NMD and premature translation termination in various sequence contexts. Targeted pseudouridylation exhibits a level of suppression comparable with that of aminoglycoside antibiotic treatments. When targeted pseudouridylation is combined with antibiotic treatment, a much higher level of suppression is observed. Transfection of a disease model cell line (carrying a chromosomal PTC) with a designer guide RNA gene targeting the PTC also leads to nonsense suppression. Thus, targeted pseudouridylation is an RNA-directed gene-specific approach that suppresses NMD and concurrently promotes PTC readthrough.

[1]  L. Romão,et al.  Nonsense suppression therapies in human genetic diseases , 2021, Cellular and Molecular Life Sciences.

[2]  Md. Al Mehedi Hasan,et al.  Identification of RNA pseudouridine sites using deep learning approaches , 2021, PloS one.

[3]  J. Lueck,et al.  Therapeutic promise of engineered nonsense suppressor tRNAs , 2021, Wiley interdisciplinary reviews. RNA.

[4]  L. Maquat,et al.  Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay , 2021, Nature Cell Biology.

[5]  Chao Niu,et al.  Role of smooth muscle cells in Cardiovascular Disease , 2020, International journal of biological sciences.

[6]  Yi-Tao Yu,et al.  Suppression of Nonsense Mutations by New Emerging Technologies , 2020, International journal of molecular sciences.

[7]  Yi-Tao Yu,et al.  Pseudouridine-mediated stop codon readthrough in S. cerevisiae is sequence context–independent , 2020, RNA.

[8]  D. Corey,et al.  Delivery of Antisense Oligonucleotides to the Cornea. , 2020, Nucleic acid therapeutics.

[9]  M. Varano,et al.  Gene Therapy in Retinal Dystrophies , 2019, International journal of molecular sciences.

[10]  Joshua D. Jones,et al.  Pseudouridinylation of mRNA coding sequences alters translation , 2019, Proceedings of the National Academy of Sciences.

[11]  R. Green,et al.  Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides , 2019, bioRxiv.

[12]  E. Kelly,et al.  Base-pairing interactions between substrate RNA and H/ACA guide RNA modulate the kinetics of pseudouridylation, but not the affinity of substrate binding by H/ACA small nucleolar ribonucleoproteins , 2019, RNA.

[13]  L. Maquat,et al.  Quality and quantity control of gene expression by nonsense-mediated mRNA decay , 2019, Nature Reviews Molecular Cell Biology.

[14]  A. Sivachenko,et al.  Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  Yi-Tao Yu,et al.  Guide-substrate base-pairing requirement for box H/ACA RNA-guided RNA pseudouridylation , 2018, RNA.

[16]  K. Wiman,et al.  Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors , 2018, Front. Oncol..

[17]  K. Wiman,et al.  Targeting mutant p53 for efficient cancer therapy , 2017, Nature Reviews Cancer.

[18]  Evan A Caton,et al.  Efficient RNA pseudouridylation by eukaryotic H/ACA ribonucleoproteins requires high affinity binding and correct positioning of guide RNA , 2017, Nucleic acids research.

[19]  D. Bedwell,et al.  Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences , 2017, Human molecular genetics.

[20]  Dennis W Dickson,et al.  Pathology of Neurodegenerative Diseases. , 2017, Cold Spring Harbor perspectives in biology.

[21]  A. Jacobson,et al.  Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression , 2016, Proceedings of the National Academy of Sciences.

[22]  Wei Chen,et al.  iRNA-PseU: Identifying RNA pseudouridine sites , 2016, Molecular therapy. Nucleic acids.

[23]  S. Brogna,et al.  The Meaning of NMD: Translate or Perish. , 2016, Trends in genetics : TIG.

[24]  B. Korf,et al.  Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I , 2016, Disease Models & Mechanisms.

[25]  A. Heger,et al.  UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy , 2016, bioRxiv.

[26]  Yi-Tao Yu,et al.  Pseudouridines in U2 snRNA stimulate the ATPase activity of Prp5 during spliceosome assembly , 2016, The EMBO journal.

[27]  Gene W. Yeo,et al.  Robust transcriptome-wide discovery of RNA binding protein binding sites with enhanced CLIP (eCLIP) , 2016, Nature Methods.

[28]  Yan-Hui Li,et al.  PPUS: a web server to predict PUS-specific pseudouridine sites , 2015, Bioinform..

[29]  P. Sharp,et al.  Detained introns are a novel, widespread class of post-transcriptionally spliced introns , 2015, Genes & development.

[30]  Yi-Tao Yu,et al.  RNA-guided isomerization of uridine to pseudouridine—pseudouridylation , 2014, RNA biology.

[31]  W. Gilbert,et al.  Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells , 2014, Nature.

[32]  A. Hinzpeter,et al.  Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. , 2014, The international journal of biochemistry & cell biology.

[33]  John Karijolich,et al.  Therapeutic suppression of premature termination codons: Mechanisms and clinical considerations (Review) , 2014, International journal of molecular medicine.

[34]  A. T. van der Ploeg,et al.  Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients. , 2013, Molecular genetics and metabolism.

[35]  V. Ramakrishnan,et al.  Unusual base pairing during the decoding of a stop codon by the ribosome , 2013, Nature.

[36]  Swee Lay Thein,et al.  The molecular basis of β-thalassemia. , 2013, Cold Spring Harbor perspectives in medicine.

[37]  L. Maquat,et al.  Rules that govern UPF1 binding to mRNA 3′ UTRs , 2013, Proceedings of the National Academy of Sciences.

[38]  S. Peltz,et al.  Ataluren as an agent for therapeutic nonsense suppression. , 2013, Annual review of medicine.

[39]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[40]  Yi-Tao Yu,et al.  Inducing nonsense suppression by targeted pseudouridylation , 2012, Nature Protocols.

[41]  D. Bedwell,et al.  Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases , 2011, Wiley interdisciplinary reviews. RNA.

[42]  John Karijolich,et al.  Modifying the genetic code: Converting nonsense codons into sense codons by targeted pseudouridylation , 2011, Nature.

[43]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[44]  T. Kiss,et al.  Box H/ACA small ribonucleoproteins. , 2010, Molecular cell.

[45]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[46]  T. Schoeb,et al.  Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. , 2010, Molecular genetics and metabolism.

[47]  C. Heier,et al.  Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. , 2009, Human molecular genetics.

[48]  P. Schattner,et al.  Functionality and substrate specificity of human box H/ACA guide RNAs. , 2008, RNA.

[49]  B. Kerem,et al.  Introducing sense into nonsense in treatments of human genetic diseases. , 2008, Trends in genetics : TIG.

[50]  Matthew Mort,et al.  A meta‐analysis of nonsense mutations causing human genetic disease , 2008, Human mutation.

[51]  B. Kerem,et al.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. , 2007, The Journal of clinical investigation.

[52]  A. Terzic,et al.  Aminoglycoside‐induced Translational Read‐through in Disease: Overcoming Nonsense Mutations by Pharmacogenetic Therapy , 2007, Clinical pharmacology and therapeutics.

[53]  X. Darzacq,et al.  Cotranscriptional Recognition of Human Intronic Box H/ACA snoRNAs Occurs in a Splicing-Independent Manner , 2006, Molecular and Cellular Biology.

[54]  T. Kiss,et al.  Biogenesis and intranuclear trafficking of human box C/D and H/ACA RNPs. , 2006, Cold Spring Harbor symposia on quantitative biology.

[55]  U. Meier,et al.  The many facets of H/ACA ribonucleoproteins , 2005, Chromosoma.

[56]  E. Bertrand,et al.  Human Box H/ACA Pseudouridylation Guide RNA Machinery , 2004, Molecular and Cellular Biology.

[57]  chen wang,et al.  Architecture and assembly of mammalian H/ACA small nucleolar and telomerase ribonucleoproteins , 2004, The EMBO journal.

[58]  L. Maquat.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.

[59]  Xinliang Zhao,et al.  Pseudouridylation (Ψ) of U2 snRNA in S.cerevisiae is catalyzed by an RNA‐independent mechanism , 2003, The EMBO journal.

[60]  R. Terns,et al.  An H/ACA guide RNA directs U2 pseudouridylation at two different sites in the branchpoint recognition region in Xenopus oocytes. , 2002, RNA.

[61]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[62]  J. Mendell,et al.  When the Message Goes Awry Disease-Producing Mutations that Influence mRNA Content and Performance , 2001, Cell.

[63]  P. Legrain,et al.  Yeast RNase III as a key processing enzyme in small nucleolar RNAs metabolism. , 1998, Journal of molecular biology.

[64]  J. Steitz,et al.  Modifications of U2 snRNA are required for snRNP assembly and pre‐mRNA splicing , 1998, The EMBO journal.

[65]  Maurille J. Fournier,et al.  The Pseudouridine Residues of rRNA: Number, Location, Biosynthesis, and Function , 1998 .

[66]  D. Bentley,et al.  5'-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II. , 1997, Genes & development.

[67]  Tamás Kiss,et al.  Site-Specific Pseudouridine Formation in Preribosomal RNA Is Guided by Small Nucleolar RNAs , 1997, Cell.

[68]  J. Ni,et al.  Small Nucleolar RNAs Direct Site-Specific Synthesis of Pseudouridine in Ribosomal RNA , 1997, Cell.

[69]  J. Steitz,et al.  A mammalian gene with introns instead of exons generating stable RNA products , 1996, Nature.

[70]  H. Scott,et al.  Molecular genetics of muccpolysaccharidosis type I: Diagnostic, clinical, and biological implications , 1995 .

[71]  R. Martin,et al.  Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs. , 1994, Nucleic acids research.

[72]  J Ofengand,et al.  Four newly located pseudouridylate residues in Escherichia coli 23S ribosomal RNA are all at the peptidyltransferase center: analysis by the application of a new sequencing technique. , 1993, Biochemistry.

[73]  J. Liu,et al.  Mouse U14 snRNA is encoded in an intron of the mouse cognate hsc70 heat shock gene. , 1990, Nucleic acids research.

[74]  M. Pirastu,et al.  β THALASSAEMIA MUTATIONS IN MEDITERRANEAN POPULATIONS , 1989, British journal of haematology.

[75]  R. Gorlin,et al.  A nonpathologic allele (IW) for low alpha-L-iduronidase enzyme activity vis-a-vis prenatal diagnosis of Hurler syndrome. , 1987, American journal of medical genetics.

[76]  J. Hopwood,et al.  A fluorometric assay using 4-methylumbelliferyl α-l-iduronide for the estimation of α-l-iduronidase activity and the detection of Hurler and Scheie syndromes , 1979 .

[77]  A. Shatkin.  Capping of eucaryotic mRNAs , 1976, Cell.